US Stocks

Tango Therapeutics, Inc.

Tango Therapeutics is a biotech firm in Cambridge, Mass that discovers and develops cancer drugs, notably its lead program TNG908 for cancers with methylthioadenosine phosphorylase deletions. The company also has a strategic collaboration with Gilead Sciences for the discovery, development, and commercialization of a pipeline of therapies for cancer patients. Founded in 2017, Tango Therapeutics is currently developing Ubiquitin-specific protease 1 and Target 3 for BRCA1 or BRCA2-mutant and STK11-mutant cancer patients.